- Home
- APAD vs ALLO Comparison
APAD vs ALLO Comparison
Compare APAD & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APAD | ALLO |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.1M | 252.9M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | APAD | ALLO |
|---|---|---|
| Price | $10.05 | $1.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 138.5K | ★ 2.5M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $72.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $0.86 |
| 52 Week High | $10.21 | $3.78 |
Technical Indicators
Market Signals| Indicator | APAD | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.63 |
| Support Level | N/A | $1.41 |
| Resistance Level | N/A | $1.57 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 64.15 |
Price Performance
Historical ComparisonAbout APAD A Paradise Acquisition Corp. Class A Ordinary Shares
A Paradise Acquisition Corp is a blank check company.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.